Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
光激活纳米颗粒阿霉素间质化学光疗
基本信息
- 批准号:10010747
- 负责人:
- 金额:$ 39.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-06 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventAnimalsBenchmarkingBiotechnologyBlood CirculationBlood VesselsBuffaloesCancer PatientClinicClinical ResearchCombination Drug TherapyComprehensive Cancer CenterComputer ModelsDataDoseDoxorubicinDrug Delivery SystemsDrug KineticsDrug vehicleEffectivenessElementsEncapsulatedFormulationGoalsHalf-LifeHepG2HourHumanIn VitroLasersLicensingLightLightingLiposomesLiver neoplasmsMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of liverMethodsModelingMusNanotechnologyNational Cancer InstituteNeckOryctolagus cuniculusPUVA PhotochemotherapyPatientsPharmaceutical PreparationsPharmacologyPhasePhospholipidsPhototherapyPorphyrinsPre-Clinical ModelPrimary NeoplasmPrimary carcinoma of the liver cellsPropertyRattusRodentRoswell Park Cancer InstituteSafetySerumSmall Business Technology Transfer ResearchSurvival RateSystemTestingTherapeuticToxic effectTranslatingUltrasonographyWoodchuckanti-cancerbaseclinically relevantcommercializationdosimetryeffective therapyhepatic necrosisimage guidedimprovedin vivointerstitiallight dosimetrynanoparticulatenoveloutcome forecastphase 2 studypreclinical studyprimary endpointresponsesafety testingsecondary endpointsubcutaneoussuccesstreatment planningtumortumor ablationtumor growth
项目摘要
SUMMARY
Our goal is to advance the commercialization of interstitial chemo-phototherapy (I-CPT) as a potent antitumor
therapeutic option for locally advanced tumors. This application will focus on providing a proof of concept for
the benefit of I-CPT in the treatment locally advanced hepatocellular carcinoma (HCC). Patients with
inoperable locally advanced HCC have a poor prognosis with a 5-year survival rate of just 31%. The
combination of chemotherapy and phototherapy (CPT) involves administering a single agent such as
PhotoDox, a novel long-circulating, doxorubicin in porphyrin-phospholipid liposome formulation. The major
advantages of PhotoDox are: 1) it is thermally independent; 2) has rapid drug release upon 665-nm light
administration; 3) is long-circulating (~22 hour half-life), serum stable, and otherwise like DOXIL®; and 4) has
been demonstrated to be effective in multiple tumor models. PhotoDox was tested by the National Cancer
Institute Nanotechnology Characterization Lab, and was found to be similar to DOXIL® in in vitro toxicity and in
vivo pharmacokinetic studies.
POP Biotechnologies, Inc. has an exclusive license for PhotoDox. Dr. Shafirstein's team at Roswell Park
Cancer Institute (RPCI) has developed and validated a novel system to provide specific light dosimetry in
large tumors. In this STTR application, POP Biotechnologies will combine PhotoDox with Dr. Shafirstein’s
treatment planning approach to optimize and guide I-CPT for effective therapy of locally advanced liver tumors
by accomplishing the following aims:
Aim 1: To define light irradiance and fluence for effective I-CPT in subcutaneous HepG2 tumors.
The PI validated finite element method approach will be used to guide a light dose finding study to define a
safe and effective intratumoral light irradiance and fluence for I-CPT with PhotoDox. We will address the key
question: What is the optimal intratumoral light irradiance and fluence for I-CPT with PhotoDox?
Aim 2: Demonstrate the effectiveness of I-CPT in an orthotopic liver cancer rat model.
We will use the FEM to translate the optimal interstitial light delivery determined in murine tumors (Aim 1) to
larger orthotopic liver cancer in rats. We will address the key question: Can we deliver an effective I-CPT with
PhotoDox to an orthotopic model of liver tumor?
This translational Phase I project will provide required data to guide a Phase II study where our teams will test
and study I-CPT with PhotoDox in a spontaneous woodchuck HCC (available at RPCI) that is relevant to
understanding I-CPT treatment in the context of human liver cancer patients. If successful, I-CPT with
PhotoDox stands to benefit the majority of new liver cancer patients, who have inoperable and problematic
primary tumors.
摘要
我们的目标是推动间质化学-光疗(i-CPT)作为一种有效的抗肿瘤药物的商业化
局部晚期肿瘤的治疗选择。此应用程序将重点提供以下方面的概念证明
I-CPT在治疗局部晚期肝细胞癌中的作用患有疾病的患者
无法手术的局部晚期肝细胞癌预后较差,5年存活率仅为31%。这个
化疗和光疗的组合(CPT)包括给予单一的药物,如
一种新型的长循环阿霉素卟啉磷脂脂质体制剂。少校
PhotoDox的优点是:1)它是热不依赖的;2)在665 nm的光下可以快速释放药物
给药;3)长循环(~22小时半衰期),血清稳定,其他如Doxil®;以及4)具有
已被证明在多种肿瘤模型中是有效的。美国国家癌症研究所对PhotoDox进行了检测
研究所纳米技术表征实验室,并被发现在体外毒性和在
体内药代动力学研究。
POP生物技术公司拥有PhotoDox的独家许可证。沙菲尔斯坦博士在罗斯威尔公园的团队
癌症研究所(RPCI)开发并验证了一种新系统,以提供特定的光剂量学在
巨大的肿瘤。在这个STTR应用程序中,POP BioTechnologies将把PhotoDox和Shafistein博士的
优化和指导I-CPT治疗局部晚期肝肿瘤的治疗计划方法
通过实现以下目标:
目的1:确定在HepG2皮下肿瘤中进行有效的I-CPT的光照强度和光通量。
PI验证的有限元方法将用于指导光剂量发现研究,以定义
PhotoDox I-CPT瘤内光照度和光通量的安全有效。我们将解决关键问题
问:使用PhotoDox的I-CPT的最佳肿瘤内光照度和光通量是多少?
目的2:验证I-CPT在大鼠原位肝癌模型中的疗效。
我们将使用有限元将在小鼠肿瘤中确定的最佳间质光传递(目标1)转换为
较大的大鼠原位肝癌。我们将解决关键问题:我们能否提供有效的I-CPT
用PhotoDox制作原位肝肿瘤模型?
此翻译第一阶段项目将提供必要的数据,以指导我们的团队将进行测试的第二阶段研究
和研究I-CPT与PhotoDox在自发性土拨鼠肝癌中的作用(可在RPCI处获得),这与
在人类肝癌患者的背景下理解I-CPT治疗。如果成功,I-CPT与
PhotoDox将使大多数新发的肝癌患者受益,他们患有无法手术和有问题的
原发肿瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GAL SHAFIRSTEIN其他文献
GAL SHAFIRSTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GAL SHAFIRSTEIN', 18)}}的其他基金
Optical Surface Applicator Light Dosimetry for Ruthenium-based Photosensitizer Mediated Intraoperative Photodynamic Therapy
用于钌基光敏剂介导的术中光动力治疗的光学表面照射器光剂量测定
- 批准号:
10303270 - 财政年份:2021
- 资助金额:
$ 39.99万 - 项目类别:
Optical Surface Applicator Light Dosimetry for Ruthenium-based Photosensitizer Mediated Intraoperative Photodynamic Therapy
用于钌基光敏剂介导的术中光动力治疗的光学表面照射器光剂量测定
- 批准号:
10454364 - 财政年份:2021
- 资助金额:
$ 39.99万 - 项目类别:
Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
光激活纳米颗粒阿霉素间质化学光疗
- 批准号:
10700814 - 财政年份:2020
- 资助金额:
$ 39.99万 - 项目类别:
Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
光激活纳米颗粒阿霉素间质化学光疗
- 批准号:
10384796 - 财政年份:2020
- 资助金额:
$ 39.99万 - 项目类别:
Integrated Image-Guided Dosimetry and Treatment Planning for Photodynamic Therapy
光动力治疗的集成图像引导剂量测定和治疗计划
- 批准号:
9187830 - 财政年份:2015
- 资助金额:
$ 39.99万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 39.99万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 39.99万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 39.99万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 39.99万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 39.99万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 39.99万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 39.99万 - 项目类别: